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Abstract: In vitro run-off transcription from a double-stranded DNA template by T7 RNA polymerase is an elegant 
way to obtain highly pure and uniform RNA oligonucleotides of lengths ranging from about 15 to several thousand 
nucleotides. Here we describe the different strategies applied and optimized in our laboratory to enzymatically 
synthesize RNAs as necessary when working at the interface of bioinorganic chemistry, coordination chemistry, 
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make the RNA oneself by in vitro transcrip-
tion with T7 polymerase, which is a standard 
and well-described procedure applied in 
numerous biochemical laboratories around 
the world [6]. Our research focuses on the 
interaction of metal ions with ribozymes, 
i.e. catalytic RNAs, and includes structure 
determination [3][4] of these RNAs by both 
NMR and X-ray crystallography (see also 
[1]) [2][5][7][8]. Consequently, we have 
special requirements regarding yield and 
uniformity in length, as well as buffers and 
metal ions employed during transcription 
and purification. We have therefore set up 
and optimized an efficient system of RNA 
transcription and purification to synthesize 
RNAs according to our needs.
2. General Considerations and 
Chemical Synthesis of RNA
RNA is commonly prepared by one of 
the three following ways: 
(i)   by direct isolation and purification 
from the biological source, which are 
not further described in this paper;
(ii)  by chemical synthesis on a nucleic 
acid synthesizer;
(iii)  by in vitro run-off transcription from 
dsDNA (double-stranded DNA, see 
List of Abbreviations below) using T7 
polymerase.
The chemical synthesis of RNA se-
quences has been described in detail [9] 
and is usually carried out by companies or 
in specialized laboratories [10]. Standar-
dized chemical synthesis of RNA is one 
of the significant achievements in RNA 
(bio)chemistry of the past few years and 
is the method of choice in the following 
cases: 
(i)   if short sequences (<15 nt) are needed, 
which are usually difficult to obtain in 
good yield and purity by transcrip-
tion;
(ii)  if a specific sequence at the 5ʹ-end of 
the RNA is required that cannot be 
obtained by in vitro transcription (see 
also below);
(iii)  if non-standard nucleotide derivatives 
have to be incorporated site-specifi-
cally into the sequence. Such modi-
fications are for example heavy-atom 
derivatives, e.g. 5-bromo- and 5-io-
douridine [11], or selenium-modified 
ribonucleotides [12][13], all of which 
are needed for X-ray crystallography. 
Other derivatives serve as fluorescent 
markers [14] or are used for NAIM 
[15][16] and NAIS studies [17].
Major limitations of the chemical syn-
thesis of RNA are the length of the se-
quence, the amount of RNA which can be 
produced, and the price. As every nucleo-
tide is introduced with an efficiency of 
about 97%, yields decrease dramatically 
for RNA sequences longer than 30 nt. Other 
encountered disadvantages of commercial-
ly available chemically synthesized RNA 
are impurities such as capped aborts and 
incompletely deprotected sequences, in ad-
dition to prohibitive prices, if large amounts 
are needed.
For many applications it is therefore 
useful and necessary to synthesize the 
RNA by in vitro transcription. In the fol-
lowing sections, we will shortly describe 
methods for the synthesis of RNA taking 
into account its future application, as well 
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1. Introduction
Interdisciplinary research is gaining in-
creasingly in importance and thus the bor-
ders between chemistry and other research 
fields are vanishing more and more. In our 
laboratory we work at the interface between 
structural biology, bioinorganic chemistry, 
and inorganic chemistry of RNA [1–5]. In 
this short review we provide a general over-
view concerning different methods of RNA 
synthesis that we have optimized according 
to our requirements.
The RNA oligonucleotides we are study-
ing range from 7 to 2500 nucleotides (nt) 
in length. RNAs are commercially available 
only to a limited extent: Although chemical 
synthesis up to a length of about 80 nucleo-
tides is possible, with increasing length 
(>20 nt), yields decrease rapidly and costs 
become prohibitive. A good alternative is to 
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as sequence, purity, and length uniformity 
of the target RNA. 
3. In vitro Transcription
To bypass the limitations of chemical syn-
thesis indicated above, the enzymatic RNA 
synthesis by RNA polymerases is a good 
alternative. Bacteriophage RNA polymer-
ases, such as T7, are exceptionally active in 
in vitro transcription and have the advantage 
of initiating transcription at a single site and 
to terminate quite precisely [6]. Like many 
enzymes, T7 can be obtained commercially. 
However, as soon as milligram amounts of 
RNA are needed, as is the case for any struc-
tural investigation, T7 needs to be applied in 
high concentrations, which again becomes 
financially prohibitive. We therefore effi-
ciently express T7 in our laboratory and have 
optimized its purification.
3.1. T7 RNA polymerase
Bacteriophage T7 RNA polymerase is a 
99 kDa enzyme composed of a single poly-
peptide chain. This protein recognizes a spe-
cific dsDNA sequence of 17 nt in length, the 
so-called promoter sequence (Fig. 1). Tran-
scription, i.e. the sequence-specific genera-
tion of a RNA chain from NTPs, is initiated 
after the TATA box at position +1 (Fig. 1). 
T7 thereby melts the dsDNA template rid-
ing along the template strand, which encodes 
the wanted RNA sequence [6]. In contrast to 
DNA polymerases, addition of an oligonucle-
otide-primer is not necessary. Incorporation 
of the first nucleotides is called the initiation 
phase, which is characterized by abortive cy-
cling, a process leading to the production of 
short RNA sequences of typically 2–6 nt in 
length [18]. After a conformational change 
of the enzyme, the elongation complex in 
form of a RNA-primed DNA template is 
formed, which now completes transcription 
of the entire sequence in a highly processive 
and accurate manner [19].
In our group, we express T7 RNA poly-
merase from the E. coli strain BL21(DE3) 
[20] containing the expression plasmid 
pBH112. The plasmid encodes (i) for T7, 
to which a 6x His tag is added, and (ii) for 
an ampicillin resistance. Typically, two 
500 ml cell cultures are grown in shaking 
flasks at 37 °C in LB medium containing 
ampicillin. As soon as an optical density 
of 0.6 at 600 nm is reached, IPTG is add-
ed to a final concentration of 0.4 mM to 
induce expression of T7. Four hours af-
ter induction, the cells are harvested by 
centrifugation at 6000 g for 4 min lead-
ing to pellets, which can be stored at –80 
°C. Cell lysis is achieved by resuspension 
in 20 mM Tris-HCl buffer (pH 8.0), 500 
mM NaCl, 1% deoxycholate, 0.05 mM 
PMSF and subsequent sonification. After 
centrifugation, the viscous brown super-
natant is applied to a Ni2+-NTA column 
and washed with 10 mM imidazole in 20 
mM Tris-HCl pH 8.0, 500 mM NaCl. The 
bound T7 RNA polymerase is then eluted 
with 100 mM imidazole in the same buf-
fer and concentrated by centrifugation 
through filter devices.
In order to obtain highly pure and active 
T7 polymerase in good yields we added the 
following steps to the general protocol: The 
polymerase is further purified by chroma-
tography on a cation exchange column that 
has been equilibrated with 30 mM HEPES 
buffer (pH 7.5), 100 mM potassium gluta-
mate, 0.25 mM EDTA, 0.05 % Tween-20, 
1 mM DTT. The bound protein is eluted by 
application of a 250 ml gradient of NaCl 
ranging from 0 to 1 M. The peak fractions 
eluting near 200 mM NaCl are pooled and 
concentrated in filter devices to a volume 
of typically 6 ml. After addition of an equal 
volume of glycerol, the polymerase is 
stored at –20 °C for immediate use or flash 
frozen in liquid nitrogen for long-term stor-
age at –80 °C. This procedure yields at least 
50 mg of pure and highly active T7 RNA 
polymerase. 
3.2. General Transcription 
Requirements
Before considering the specific require-
ments and conditions for transcription of 
RNA of different lengths (see Sections 3.3 
and 3.4) we first summarize the important 
points to be considered in all cases.
As mentioned above, the promoter re-
gion needs to be double-stranded to bind 
T7. The following DNA template sequence 
can be single-stranded. Thus, the so-called 
template strand contains (from 3ʹ to 5ʹ) the 
promoter sequence followed by the coding 
sequence (‘template’). In contrast, the top 
strand can be much shorter encompassing 
only the complementary promoter sequence 
plus some additional Gs. In our experience, 
fully dsDNA oligonucleotides usually give 
the best yields. However, there are no rules 
about which variation is the best: On the 
one side, a fully dsDNA template often in-
creases transcription yield, but on the other 
side a short top strand can be universally 
used for any template strand. 
The DNA template can be obtained from 
different sources: (i) From two chemically 
synthesized strands, (ii) by amplification 
from a tiny amount of dsDNA by PCR, or 
(iii) from a linearized plasmid [21].
The first six nucleotides at positions +1 
to +6 have the greatest impact on transcrip-
tion initiation and the subsequent structural 
change of T7 to the elongation complex; 
hence, these nucleotides determine the 
yield of the target RNA to a large amount. 
A guanosine at position +1 is by far the best 
starter, but in principle any one of the four 
nucleotides work [22]. Many possible com-
binations of G, A, C, and U have been tested 
for the first six nucleotides [22]. Some ex-
cellent starting sequences are: GGGAGA, 
GGGAUC, GGCAAC, or GGCGCU.
Once a DNA template is at hand, stan-
dard conditions for transcription are as fol-
lows: 40 mM Tris-HCl (pH 7.5), 40 mM 
DTT, 2 mM spermidine, 0.01% Triton-X 
100, 5 mM NTP each, 10–50 mM MgCl2, 
Fig. 1. Transcription of RNA from a dsDNA template. The T7 promoter region excluding the TATA box (position –4 to –1) is marked by a grey box. 
Transcription starts at position +1, as indicated by an arrow. (A) Short RNA sequences are transcribed from a synthetic partially ss or ds DNA template. 
The top strand oligonucleotide must contain the nucleotides –17 to +1. The complementary template sequence (shown in grey letters) is not absolutely 
required. The template strand encompasses the T7 promoter region plus the coding template sequence. (B) Larger RNA sequences are often transcribed 
from a linearized plasmid. The endonuclease cleavage site, for EcoRI in this case, is indicated by an asterisk.
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1.2 μM template or 5–10 μg linearized plas-
mid/ml transcription solution. 
T7 RNA polymerase is always added 
last in an amount depending on the quality 
and concentration of the batch and mixed 
very gently. The DTT solution must be 
prepared freshly, the spermidine and NTP 
stock solutions can be stored at –20 °C for 
several months. 
The total volume of a transcription reac-
tion is scalable from a few microliters up to 
many milliliters and depends mainly on the 
subsequent application of the RNA. Expe-
rience shows that the yield increases when 
the transcription reaction is carried out in 
small aliquots, e.g. 1 ml each. After mixing, 
the transcription reaction is incubated at 37 
°C overnight (short constructs) or for 2–4 h 
(very long constructs).
Variables of the standard conditions 
include the concentrations of NTPs (1–10 
mM), MgCl2 (10–50 mM), and the dsDNA 
template. The concentration range for short 
oligonucleotide-templates is 0.6–2 μM 
while for plasmid-substrates the concen-
tration varies between 5–15 μg/ml. Addi-
tion of BSA (100 μg/ml) or PEG 8000 (80 
mg/ml) sometimes also increases the yield. 
Our experience shows that the addition of 
5 mM GMP can increase transcription ef-
ficiency significantly. GMP is only inserted 
as the starting nucleotide at the 5'-end, but 
as the initiation of transcription is an im-
portant yield-determining factor, increasing 
the total guanosine concentration can be a 
good choice. Obviously, the addition of 
GMP will lead to a mixture of triphosphate 
and monophosphate 5'-termini, which are 
well detectable by NMR [4]. This (mostly 
irrelevant) inhomogeneity can be overcome 
by subsequent treatment with calf intesti-
nal alkaline phosphatase (CIAP) resulting 
in homogeneous 5'-hydroxyl ends. 
In most cases, standard reaction condi-
tions as given above will yield sufficient 
amounts of RNA for biochemical studies. 
However, for NMR and X-ray applica-
tions larger amounts of RNA are needed, 
and thus the reaction conditions have to be 
optimized for each new template, which is 
usually done by small-scale (50 μl) reac-
tions.
3.3. Transcription of Short RNAs 
(10–50 nt)
In vitro transcription of short RNAs, i.e. 
about 10–50 nt in length, is usually done 
from chemically synthesized dsDNA tem-
plates. Including the promoter region (Fig. 
1), the DNA template will have a length of 
up to 70 nt, and can thus be readily pur-
chased. Prior to use, the DNA has to be pu-
rified by PAGE, followed by electroelution 
(Schleicher&Schuell) and ethanol precipi-
tation. 
To obtain milligram quantities of RNA, 
usually large-scale transcriptions (10 ml) 
are run overnight (although 6–8 h is mostly 
sufficient). Evidently, for large-scale tran-
scription high concentrations of NTPs, ds-
DNA template, and T7 are needed.
T7 has the peculiarity to run off the DNA 
template strand and sometimes unspecifi-
cally add up to five or six nucleotides at the 
3ʹ-end of the RNA transcripts. To separate 
these so-called N+1, N+2, etc. run-off tran-
scripts, as well as abortive shorter sequences 
from the target RNA, high resolution PAGE 
is the method of choice. Under large-scale 
conditions as described here, a white pre-
cipitate composed of Mg2P2O7 (magnesium 
pyrophosphate, i.e. diphosphate) is often 
formed during the reaction. This precipitate 
should be removed by centrifugation prior 
to PAGE. Alternatively pyrophosphatase 
can be added during transcription efficient-
ly hydrolyzing the precipitate. The RNA is 
purified by PAGE followed by electroelu-
tion and ethanol precipitation. As a last step, 
the target RNA is exchanged into water or 
a suitable buffer by vivaspin concentration 
(Vivaspin concentrator from Vivascience). 
It should be mentioned here that the often 
applied Tris buffer should be avoided when 
working with metal ions, as this molecule is 
a good ligand for many Mn+ ions [23].
3.4. Transcription of Long RNAs 
(>50 nt)
As the length of chemically synthesized 
DNA reaches its practical limit at around 80 
nt, transcription of RNA sequences >50 nt is 
usually done using plasmid DNA as a tem-
plate. The sequence of interest is obtained 
by common PCR or by colony PCR directly 
from the organism and is then cloned down-
stream of a T7 promoter into a multicopy 
plasmid by standard cloning procedures 
[24]. A variety of transcription vectors con-
taining a T7 promoter sequence leading a 
multiple cloning site is commercially avail-
able. We usually follow a slightly differ-
ent strategy and place the T7 promoter by 
PCR directly upstream of the coding DNA 
sequence. This strategy prevents the inser-
tion of unwanted 5ʹ-terminal nucleotides. 
However, it leads to some restrictions on 
the first six nucleotides of the transcript as 
discussed above.
T7 moves along the dsDNA template as 
long as possible, i.e. there is no stop sig-
nal. Thus, the plasmid has to be cleaved 
sequence specifically by a restriction en-
donuclease at the 3ʹ-end of the coding se-
quence. Complete restriction is essential 
as small percentages of uncut plasmid will 
reduce the yield dramatically by production 
of very long runarounds that use up most 
of the NTPs present in solution. After com-
plete digestion with the restriction enzyme, 
the cleaved plasmid is purified with the best 
suitable purification kit.
Standard conditions are employed for 
transcription as stated above. Generally 5–
10 μg cleaved plasmid per ml transcription 
solution are used. The transcription time 
usually is between 2–4 h and gets shorter 
the longer the RNA sequences are (because 
of increasing sensitivity to degradation). 
Isolation of the RNA is performed as 
described above for shorter RNAs. If very 
long RNA sequences (> 200 nt) are to be 
transcribed, a better recovery from the 
polyacrylamide gel might be achieved by 
crush and soak. Thereby, the gel pieces 
containing the RNA are squeezed through 
a syringe, frozen, and eluted twice with at 
least double the volume of elution buffer 
(10 mM MOPS (pH 6–7), 1mM EDTA, 250 
mM NaCl) at 4 °C. 
The transcription using plasmid DNA 
has several advantages: The most important 
one is that there is no limitation in length 
regarding the coding DNA and thus also the 
target RNA sequence. The plasmid can be 
amplified in bacteria in a cost-saving man-
ner and purified by standard procedures.
Naturally also this method leads to N+1, 
N+2, etc. fragments, as well as sometimes 
even to inhomogeneous 5ʹ-ends [25][26]. 
Due to the small difference in length of 
these run-off transcripts compared to 
the overall length, it is often difficult to 
separate these longer transcripts from the 
target RNA by PAGE. This often causes 
problems when highly homogeneous RNA 
is needed, e.g. for X-ray crystallography. 
An elegant way to obtain a homogeneous 
transcript is shortly described in the fol-
lowing Section. 
4. RNAs with Uniform 5ʹ- and 3ʹ-
Ends
To circumvent inhomogeneous ends of 
the target RNA, ribozyme sequences can be 
placed 5ʹ and 3ʹ to the desired RNA (Fig. 
2) [27–30]. The two flanking ribozymes 
are co-transcribed yielding one long RNA 
with the target sequence in the center. Sub-
sequent to transcription, both ribozymes 
cleave at a unique location defined by a 
specific sequence.
To obtain a homogenous 5ʹ-OH end, a 
cis-acting, i.e. self-cleaving, hammerhead 
(HH) ribozyme is a good choice. The HH 
cleaves 5ʹ of a ten nucleotide sequence, 
which it recognizes through Watson-Crick 
base pairing with nucleotides being part 
of the HH. Thus, for each target RNA, the 
47-nt long HH sequence has to be individu-
ally modified and introduced between the 
T7 promoter region and the target RNA by 
PCR [30].
The usage of a cis-HDV (hepatitis delta 
virus) ribozyme sequence will lead to a 
homogeneous 3ʹ-end. The HDV-ribozyme 
cleaves 3ʹ after the last base of the target 
RNA sequence, which has to be any base 
other than G [31]. Alternatively, if a 3ʹ-G 
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is essential, one can also process the target 
RNA with the trans-cleaving, i.e. acting 
on a substrate, VS-ribozyme (Neurospora 
varkud satellite), which cuts after any base 
other than C [32–35], or by applying a 
DNAzyme [36]. Thus any desired sequence 
can be obtained. 
General protocols to produce transcripts 
with homogeneous ends using the HH/
HDV- [30] VS/HDV- ribozymes [29], and 
DNAzymes [36] were published recently.
In our laboratory, we usually apply the 
HH/HDV approach. The dsDNA template 
encompassing the T7 promoter, the HH, the 
target, and the HDV sequence, all flanked 
by two different restriction sites, is obtained 
by multistep PCR, and cloned into a plas-
mid (e.g. the pRZ-vector) (Fig. 2) [30]. The 
plasmid is amplified according to standard 
procedures and linearized as discussed 
above. The three RNA oligonucleotides re-
sulting from T7 run-off transcription, done 
under standard conditions, can then be sep-
arated easily by PAGE. 
Sometimes incomplete cleavage of the 
flanking ribozymes occurs. This can be 
overcome by adjusting the MgCl2 concen-
tration to 40 mM and performing additional 
thermal cycling after transcription [30]: The 
solution is heated 1 min at 72 °C, 5 min at 
65 °C and 10 min at 37 °C. This process 
is repeated three times and significantly in-
creases the yield (Fig. 3).
5. Further Purification Methods
As described above, after transcription 
the RNA is purified by denaturing PAGE 
to separate the target RNA from the longer 
N+1, etc. transcripts, the DNA strands, T7, 
as well as the remaining NTPs and other 
chemical substances of the transcription 
mixture. For most biochemical applications 
it is sufficient to redissolve the RNA pellet 
(after elution and ethanol precipitation) in 
the desired buffer, e.g. 10 mM MOPS (pH 
6.5), 10 μM EDTA [7].
For structural studies it is necessary to 
exchange the solvent more rigorously either 
by repeated spinning through centrifugal de-
vices or by dialysis. Sometimes it is difficult 
to completely remove all contaminations 
from the RNA sample as is evident from 
NMR spectra. In such a case the sample has 
to be purified additionally on a 1.2 m long 
gel filtration column via FPLC. Separation 
by gel filtration is carried out under native 
conditions, i.e. the secondary (and tertiary) 
structure of RNA is not melted. The same is 
true for purification on agarose gels, as well 
as under most conditions for HPLC, two 
methods which are not further described 
here. Purification using native conditions 
has a further advantage: RNA sequences 
that form hairpins, can also dimerize to 
form a long duplex. Depending on the se-
quence, both forms can be present in solu-
tion. Under denaturing conditions (i.e. in 
the presence of urea or formaldehyde), the 
molecules form only a single population of 
ssRNA molecules, which would reestablish 
the equilibrium hairpin/duplex after work-
up. In contrast, when separated under na-
tive conditions, e.g. by gel filtration, based 
on their different size, the isolated hairpin 
population will not dimerize to duplices as 
long as the molecules are not heated up to 
form single strands. 
6. Incorporation of Modified 
Nucleotides into RNA
T7 polymerase recognizes a large vari-
ety of chemically modified NTPs and incor-
porates them into the growing RNA strand 
(although not always as efficiently as the 
natural nucleotides). Naturally, these modi-
fied nucleobases are incorporated through-
out the RNA. For many biochemical pur-
poses (e.g. NAIS, NAIM, and UV cross-
linking studies), a modified NTP is added 
in addition to the four common NTPs dur-
ing transcription. This leads to a statistical 
incorporation of the modification into the 
RNA transcripts. The only position where 
a modified nucleotide can be incorporated 
site-specifically by transcription is the 5'-G 
by adding a GMP derivative, e.g. α-thio-5'-
GMP, to the transcription solution. As GTP 
is additionally present in every transcrip-
tion solution, incorporation of the modified 
GMP at the 5'-end occurs only statistically 
(see also Section 3.2). To introduce a point 
mutation into a RNA chain, the oligonucle-
otide has to be synthesized chemically. If 
longer RNA sequences are needed, it is pos-
sible to ligate this sequence harboring the 
mutation to another RNA oligonucleotide 
by a DNA/RNA ligase [37].
Usually, T7 incorporates modified 
nucleotides as one would expect, e.g. 2ʹ-
methoxy-ATP is incorporated like an A, or 
6-thio-GTP as a G. However, some excep-
tions apply, one of which is that 2-amino-
purine is incorporated in place of A, rather 
than G. When incorporating thiophosphate 
derivatives, it is important to know that T7 
will selectively produce the RP diastereo-
mer (and not the SP: nucleic acids have two 
diastereotope non-bridging oxygen atoms 
at each phosphate group, the RP points to-
wards the major and the SP towards the mi-
nor groove).
For the purpose of NMR structure de-
termination of RNAs, as done in our labo-
ratory, 13C and/or 15N labeled oligonucle-
otides are needed [1]. NTPs can be pur-
chased either uniformly 13C,15N labeled, 
or many variations thereof. Even partially 
or fully deuterated NTPs are available [38]. 
The availability of such labeled NTPs and 
the subsequent incorporation into RNA oli-
gonucleotides by in vitro transcription as 
Fig. 2. Schematic view of the preparation of a 
target RNA with homogeneous ends. The plasmid 
derived from the 5ʹ-HH/3ʹ-HDV ribozyme vector 
pRZ [30] contains the target coding sequence 
flanked by two self-cleaving ribozymes. 
Transcription leads to the target RNA neighbored 
by the HH and the HDV ribozymes. Thermal 
cycling quantitatively yields the pure target 
RNA (Fig. 3). AmpR, ampicillin resistance; HDV, 
hepatitis delta virus ribozyme; HH, hammerhead 
ribozyme; T7p, T7 promoter region.
Fig. 3. Analytical polyacrylamide-gel (8%) of 
transcription trials from the HH-targetRNA-HDV 
plasmid template as seen by UV shadowing. 
On the right side, the different species are 
indicated. Lanes 1 and 2 show the distribution 
of the different species of the RNA right after 
transcription. Lanes 3 and 4 show the same 
sample after adjusting the Mg2+ concentration 
to 40 mM and subsequent three rounds of 
thermal cycling (see also text). The HH and 
HDV ribozymes are now almost fully cleaved off 
leading to large increase in intensity of the target 
RNA band (arrow). In lanes 1 and 3 [MgCl2] 
equals 20 mM and in 2 and 4 [MgCl2] equals 
30 mM during transcription. Lane c contains 
markers of different lengths.
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described above enables us to structurally 
characterize and investigate larger RNAs 
(i.e. >20 nt) by NMR [1]. 
7. Summary
In this review we have summarized the 
various strategies to synthesize and purify 
RNAs of different lengths according to 
optimized procedures in our laboratory. In 
vitro run-off transcription by T7 RNA poly-
merase from a dsDNA template is a very 
useful method to synthesize single stranded 
RNA oligonucleotides in large quantities 
and homogeneous conformation. However, 
this is not an easy task. In biochemical ap-
plications, like activity assays of ribozymes, 
often only about 80% of a correctly folded 
and active population is achieved. Such a 
mixture is unacceptable for our NMR and 
X-ray studies: NMR spectra become unin-
terpretable and chances to crystallize RNA 
diminish rapidly. It follows that purification 
and exchange of the RNA into the desired 
solvent is a very important process for the 
research in our laboratory.
In vitro transcription is a well-estab-
lished method to synthesize RNA, but expe-
rience shows that every new RNA sequence 
behaves slightly differently. This is not only 
true for the transcription yield but also for 
the subsequent purification. It is therefore 
necessary to treat every new transcription 
like a new chemical reaction and optimize 
it accordingly – a process that can be very 
tedious. Because of the numerous small 
problems associated with RNA synthesis in 
general, as well as many new functions of 
natural RNA molecules discovered almost 
monthly, it is not surprising that several pa-
pers are published every year that address 
and improve in vitro transcription of RNA.
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